Orexigen corrects weight-loss Phase III data, shares fall
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics has said that fewer patients met the endpoints of one of the Phase III studies for its weight-loss combination candidate Contrave (naltrexone SR plus bupropion SR) than it had originally stated.